Skip to main content

Table 2 Comparison of PET and CT responses at time of discontinuation

From: Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma

 

CMR

(n = 34)

Non-CMR

(n = 4)

RECIST v1.1 response*

 CR (n = 13)

13 (38.2%)

0 (0%)

 PR (n = 21)

18 (52.9%)

3 (75.0%)

 SD (n = 4)

3 (8.8%)

1 (25.0%)

  1. Abbreviations: CR complete response, CMR, complete morphological response, PR partial response, SD stable disease
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us